



NDA 20601/S-020

**SUPPLEMENT APPROVAL**

Johnson & Johnson Consumer, Inc.  
McNeil Consumer Healthcare Division  
Attention: Doris Roberts  
Manager, Regulatory Affairs  
7050 Camp Hill Road  
Fort Washington, PA 19034-2299

Dear Ms. Roberts:

Please refer to your Supplemental New Drug Application (sNDA) dated November 16, 2016, received November 16, 2016, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Motrin® Junior Strength (ibuprofen) chewable tablets, 100 mg.

This “Changes Being Effected” supplemental new drug application provides for the addition of the “Heart attack and stroke warning” and related warning revisions to the Drug Facts labeling, in accordance with the “Changes Being Effected” (CBE-0) Supplement Request Letter from the Agency dated August 18, 2016.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the Motrin® Junior Strength (ibuprofen) chewable tablets, 100 mg labels listed below, and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<b>Submitted Labeling</b>	<b>Submission Date</b>
24-count, grape-flavored product carton	November 16, 2016
24-count, grape-flavored product immediate container (bottle)	December 16, 2016
24-count, orange-flavored product carton	November 16, 2016
24-count, orange-flavored product immediate container (bottle)	December 16, 2016

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 20601/S-020.**” Approval of this submission by FDA is not required before the labeling is used.

### **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Janice Adams-King, Safety Project Manager, at (301) 796-3713.

Sincerely,

*{See appended electronic signature page}*

Valerie Pratt, MD  
Deputy Director for Safety  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

Enclosures:

Immediate Container and Carton Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

VALERIE S PRATT  
05/15/2017